tldrdailynews.com logo

FDA Approves BridgeBio's Heart Drug, Sparking Competition with Pfizer

1 min read
Source: STAT
FDA Approves BridgeBio's Heart Drug, Sparking Competition with Pfizer
Photo: STAT
TL;DR

The FDA has approved BridgeBio's new drug, Attruby, for treating transthyretin amyloid cardiomyopathy (ATTR-CM), marking the first new treatment for this heart condition in over five years. ATTR-CM, which affects over 400,000 people globally, is caused by genetic mutations or aging, leading to amyloid deposits in the heart that impair its function. This approval represents BridgeBio's first major commercial product.

Topics:businesshealth#attr-cm#bridgebio#drug-approval#fda#health#heart-disease
Share this article
  1. BridgeBio wins FDA approval for heart disease drug  STAT
  2. FDA approves BridgeBio’s heart disease drug, setting up competition with Pfizer, Alnylam  Endpoints News
  3. Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients  Yahoo Finance
  4. BridgeBio's Attruby Wins FDA Approval: 42% Reduction in ATTR-CM Mortality & Hospitalizations | BBIO Stock News  StockTitan
  5. BridgeBio heart drug approved by FDA, setting up battle with Pfizer  BioPharma Dive

Want the full story? Read the original reporting

Read on STAT